Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for prostate cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
ProstateCancer: Screening Final Update Summary: ProstateCancer: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 18.104.22.1688 Last Build: 11/16/2018 6:27:19 PM You are here: Final Summary Is ProstateCancer Screening Right For You? (794 KB, ) ProstateCancer: Screening Release Date: May 2018 Recommendation Summary Population Recommendation Grade Men aged 55 to 69 years For men aged 55 to 69 years, the decision to undergo periodic prostate-specific (...) antigen (PSA)–based screening for prostatecancer should be an individual one. Before deciding whether to be screened, men should have an opportunity to discuss the potential benefits and harms of screening with their clinician and to incorporate their values and preferences in the decision. Screening offers a small potential benefit of reducing the chance of death from prostatecancer in some men. However, many men will experience potential harms of screening, including false-positive results
Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk ProstateCancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian ProstateCancer Group 12 Trial Adjuvant chemotherapy is standard treatment for other solid tumours, but to date has not proven effective in prostate cancer.o evaluate whether six cycles of docetaxel alone improve biochemical disease-free survival after radical prostatectomy for high-risk prostate cancer.Open-label, randomised (...) of 116 serious adverse events were recorded in Arm A and 41 in Arm B with no treatment-related deaths. Not all patients received docetaxel by protocol. The endpoint is biochemical progression and some patients received radiation treatment before the endpoint.Docetaxel without hormonal therapy did not significantly improve biochemical disease-free survival after radical prostatectomy.In this randomised trial, we tested whether chemotherapy after surgery for high-risk prostatecancer decreases the risk
A Web-Based Intervention to Reduce Distress After ProstateCancer Treatment: Development and Feasibility of the Getting Down to Coping Program in Two Different Clinical Settings Distress after prostatecancer treatment is a substantial burden for up to one-third of men diagnosed. Physical and emotional symptoms and health service use can intensify, yet men are reticent to accept support. To provide accessible support that can be cost effectively integrated into care pathways, we developed (...) a unique, Web-based, self-guided, cognitive-behavior program incorporating filmed and interactive peer support.To assess feasibility of the intervention among men experiencing distress after prostatecancer treatment. Demand, acceptability, change in distress and self-efficacy, and challenges for implementation in clinical practice were measured.A pre-post, within-participant comparison, mixed-methods research design was followed. Phase I and II were conducted in primary care psychological service
Hedgehog in prostatecancer explained 29854872 2018 11 14 2331-4737 5 3-4 2018 Mar Oncoscience Oncoscience Hedgehog in prostatecancer explained. 67-68 10.18632/oncoscience.405 Buttyan Ralph R The Vancouver Prostate Centre, Vancouver BC V6H 3Z6 Canada. Li Na N The Vancouver Prostate Centre, Vancouver BC V6H 3Z6 Canada. Massah Shabnam S The Vancouver Prostate Centre, Vancouver BC V6H 3Z6 Canada. eng Editorial 2018 04 29 United States Oncoscience 101636666 2331-4737 Androgen Receptors Gli (...) Hedgehog Steroid Receptors prostatecancer CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 04 12 2018 04 21 2018 6 2 6 0 2018 6 2 6 0 2018 6 2 6 1 epublish 29854872 10.18632/oncoscience.405 405 PMC5978441 Eur J Cancer. 2006 Mar;42(4):437-45 16406505 Prostate. 2014 Oct;74(14 ):1400-10 25132524 Cancer Chemother Pharmacol. 2016 Dec;78(6):1297-1304 27826729 Cell Mol Life Sci. 2000 Nov;57(12 ):1720-31 11130178 Oncogene. 2018 Apr;37(17 ):2313-2325 29429990 Horm Cancer. 2014
Germline genetic testing in prostatecancer â€“ further enrichment in variant histologies? 29854870 2018 11 14 2331-4737 5 3-4 2018 Mar Oncoscience Oncoscience Germline genetic testing in prostatecancer - further enrichment in variant histologies? 62-64 10.18632/oncoscience.403 Markowski Mark C MC Departments of Oncology and Urology, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD 21287, USA. Antonarakis Emmanuel S ES Departments of Oncology and Urology, Johns Hopkins Sidney Kimmel (...) Cancer Center, Baltimore, MD 21287, USA. eng Editorial 2018 04 29 United States Oncoscience 101636666 2331-4737 CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 03 29 2018 03 29 2018 6 2 6 0 2018 6 2 6 0 2018 6 2 6 1 epublish 29854870 10.18632/oncoscience.403 403 PMC5978447 N Engl J Med. 2016 Aug 4;375(5):443-53 27433846 Cell. 2015 May 21;161(5):1215-1228 26000489 Eur Urol. 2017 Jul;72 (1):34-42 28259476 Cell. 2015 Nov 5;163(4):1011-25 26544944 Eur Urol. 2018 May;73
Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With ProstateCancer Androgen deprivation therapy (ADT) for prostatecancer (PCa) is associated with increased cardiovascular mortality and sudden cardiac death, with some events occurring early after initiation of ADT. Testosterone levels are inversely associated with corrected QT (QTc) interval duration; therefore, prolongation of QTc duration could be responsible for some of these events during ADT.To
Men feel physically and psychologically ill-prepared for prostatecancer surgery Men feel physically and psychologically ill-prepared for prostatecancer surgery Discover Portal Discover Portal Men feel physically and psychologically ill-prepared for prostatecancer surgery Published on 28 November 2017 doi: Following prostatecancer surgery men often experience physical changes, such as urinary incontinence and erectile dysfunction, causing negative emotions and distress. This review found (...) that men felt poorly prepared – psychologically and physically – for the changes they might experience after surgery. Surgery was often described as "life-changing", and men described worrying about their future. NICE recommend that men and their partners/carers are fully informed about prostatecancer treatment options and their possible complications, and are supported in decision-making. This includes having access to psychosexual support at any time. This global review represents the views of men
MRI scan before biopsy could detect more prostatecancer MRI scan before biopsy could detect more prostatecancer Discover Portal Discover Portal MRI scan before biopsy could detect more prostatecancer Published on 7 March 2017 doi: In men with a raised prostate specific antigen (PSA) blood test, which can be a sign of prostatecancer, MRI scanning before standard biopsy could allow more targeted biopsies and increase diagnosis of medium and high-risk prostatecancer. In this NIHR-funded study (...) , 576 men with suspected prostatecancer received a multi-parametric (MP)-MRI scan in addition to transrectal ultrasound-guided (TRUS) biopsy. They also had template mapping (TPM) biopsy of the entire prostate to reliably diagnose cancer. Neither MP-MRI scan nor TRUS-biopsy were entirely accurate. However, if MP-MRI is used as an initial test, followed by TRUS-biopsy targeted at areas identified on the scan, 18% more cancers could be detected than by TRUS biopsy alone. It may also help avoid
Large ten-year trial on treatment of localised prostatecancer will aid management decisions Large ten-year trial on treatment of localised prostatecancer will aid management decisions Discover Portal Discover Portal Large ten-year trial on treatment of localised prostatecancer will aid management decisions Published on 15 September 2016 doi: New, long-term research indicates that active monitoring, with prompt treatment if needed, may be a better option than radical surgery or radiotherapy (...) for many men who have prostatecancer if it’s confined to the prostate gland. In the ProtecT trial, after an average of ten years, few men died of prostatecancer and there was no difference in survival between men receiving active monitoring and those who had radical treatments (which caused unpleasant side effects). But active monitoring did increase the risk of cancer progressing or spreading to other parts of the body. Longer follow-up will help to fully understand the balance between treatments
Bone-targeting drugs improve quality of life, but not survival in prostatecancer that has spread to bone Bone-targeting drugs improve quality of life, but not survival in prostatecancer that has spread to bone Discover Portal Discover Portal Bone-targeting drugs improve quality of life, but not survival in prostatecancer that has spread to bone Published on 27 September 2016 doi: The drug zoledronic acid delayed the onset of bone complications by two months in men with prostatecancer (...) strontium-89 to treat prostatecancer that has spread to the bone, but not zoledronic acid unless other treatment has failed due to costs. The branded version of zoledronic acid did not give value for money but cheaper generic versions, now available, could be a better use of NHS resources. Share your views on the research. Why was this study needed? Prostatecancer is the second most common cause of cancer deaths in men in the UK. Just over 10,000 men died from prostatecancer in 2009. The rate has
Apalutamide (Erleada) - prostatecancer Drug Approval Package: ERLEADA (apalutamide) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ERLEADA (apalutamide) This review package includes Clinical Study Reports as part of a pilot project. The Clinical Study Report section provides information for pivotal clinical trials, not for all studies in the application. Company: Janssen Biotech Application Number: 210951 Orig 1 Approval Date: 02/14/2018 Persons
Chemohormonal Therapy in Metastatic Hormone-Sensitive ProstateCancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial Purpose Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the longevity of some patients with metastatic hormone-sensitive prostatecancer. Herein, we present the outcomes of the CHAARTED (Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in ProstateCancer) trial with more mature (...) follow-up and focus on tumor volume. Patients and Methods In this phase III study, 790 patients with metastatic hormone-sensitive prostatecancer were equally randomly assigned to receive either ADT in combination with docetaxel 75 mg/m2 for up to six cycles or ADT alone. The primary end point of the study was overall survival (OS). Additional analyses of the prospectively defined low- and high-volume disease subgroups were performed. High-volume disease was defined as presence of visceral metastases
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostatecancer (LATITUDE): an international, randomised phase 3 trial In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos plus ADT in patients with newly diagnosed, high-risk, metastatic castration-naive prostatecancer (...) , by use of the Brief Pain Inventory-Short Form (BPI-SF), Brief Fatigue Inventory (BFI), Functional Assessment of Cancer Therapy Prostate scale (FACT-P), and the EuroQol (EQ-5D-5L) questionnaires. PRO analyses were an exploratory endpoint. Analyses were by intention-to-treat. Results from the first pre-planned interim analysis (Oct 31, 2016), are presented here. This ongoing study is registered with Clinicaltrials.gov, number NCT01715285.Between Feb 12, 2013, and Dec 11, 2014, 1199 patients were
Salvage Pelvic Lymph Node Dissection After Fluciclovine Positron Emission Tomography/Computed Tomography Detected ProstateCancer Recurrence Background: Multiple new systemic agents have been targeted to metastatic prostatecancer, with decreased progression of disease but no cure. Surgical management of metastatic disease has been gaining interest, primarily in the setting of high-risk prostatectomies. However, metastasis-directed surgical intervention has been employed in rare scenarios (...) dissection was carried out, with subsequent nadir of his prostate-specific antigen at 0.026. Conclusion: To our knowledge, this is the first report of salvage pelvic lymph node dissection after metastatic detection by fluciclovine PET/CT scan. Our patient experienced a complete biochemical response; however, it remains to be seen whether this will be a lasting response. Surgical resection of metastatic sites in prostatecancer offers a safe alternative to systemic therapy and avoids systemic side effects.
MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. Multiparametric magnetic resonance imaging (MRI), with or without targeted biopsy, is an alternative to standard transrectal ultrasonography-guided biopsy for prostate-cancer detection in men with a raised prostate-specific antigen level who have not undergone biopsy. However, comparative evidence is limited.In a multicenter, randomized, noninferiority trial, we assigned men with a clinical suspicion of prostatecancer who had (...) not undergone biopsy previously to undergo MRI, with or without targeted biopsy, or standard transrectal ultrasonography-guided biopsy. Men in the MRI-targeted biopsy group underwent a targeted biopsy (without standard biopsy cores) if the MRI was suggestive of prostatecancer; men whose MRI results were not suggestive of prostatecancer were not offered biopsy. Standard biopsy was a 10-to-12-core, transrectal ultrasonography-guided biopsy. The primary outcome was the proportion of men who received
Effect of a Low-Intensity PSA-Based Screening Intervention on ProstateCancer Mortality: The CAP Randomized Clinical Trial. Prostatecancer screening remains controversial because potential mortality or quality-of-life benefits may be outweighed by harms from overdetection and overtreatment.To evaluate the effect of a single prostate-specific antigen (PSA) screening intervention and standardized diagnostic pathway on prostatecancer-specific mortality.The Cluster Randomized Trial of PSA Testing (...) for ProstateCancer (CAP) included 419 582 men aged 50 to 69 years and was conducted at 573 primary care practices across the United Kingdom. Randomization and recruitment of the practices occurred between 2001 and 2009; patient follow-up ended on March 31, 2016.An invitation to attend a PSA testing clinic and receive a single PSA test vs standard (unscreened) practice.Primary outcome: prostatecancer-specific mortality at a median follow-up of 10 years. Prespecified secondary outcomes: diagnostic cancer
Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 ProstateCancer. The optimal treatment for Gleason score 9-10 prostatecancer is unknown.To compare clinical outcomes of patients with Gleason score 9-10 prostatecancer after definitive treatment.Retrospective cohort study in 12 tertiary centers (11 in the United States, 1 in Norway), with 1809 patients treated (...) between 2000 and 2013.Radical prostatectomy (RP), external beam radiotherapy (EBRT) with androgen deprivation therapy, or EBRT plus brachytherapy boost (EBRT+BT) with androgen deprivation therapy.The primary outcome was prostatecancer-specific mortality; distant metastasis-free survival and overall survival were secondary outcomes.Of 1809 men, 639 underwent RP, 734 EBRT, and 436 EBRT+BT. Median ages were 61, 67.7, and 67.5 years; median follow-up was 4.2, 5.1, and 6.3 years, respectively. By 10 years
Prostatecancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone Prostatecancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone | European Medicines Agency Search Search Menu Prostatecancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone Press release 09/03/2018 Ongoing clinical study shows an increased risk of death and fractures with the combination The European Medicines Agency (EMA) has recommended contraindicating (...) the use of the prostatecancer medicine Xofigo (radium-223 dichloride) with Zytiga (abiraterone acetate) and prednisone/prednisolone, due to an increased risk of death and fractures with this combination. EMA's ( ) has reviewed the preliminary data from an ongoing clinical study in metastatic prostatecancer patients. In this study 34.7% of patients treated with Xofigo, Zytiga and prednisone/prednisolone have died so far, compared with 28.2% of patients given placebo, Zytiga and prednisone
Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostatecancer Randomized evidence for extreme hypofractionation in prostatecancer is lacking. We aimed to identify differences in toxicity and quality-of-life outcomes between standard fractionation and extreme hypofractionated radiation in a phase 3 randomized trial.We analyzed the results of the first 75 patients in our (...) phase 3 trial, comparing 38 Gy relative biologic effectiveness (RBE) in 5 fractions (n = 46) versus 79.2 Gy RBE in 44 fractions (n = 29). Patients received proton radiation using fiducials and daily image guidance. We evaluated American Urological Association Symptom Index (AUASI), adverse events (AEs), and Expanded Prostate Index Composite (EPIC) domains. The primary endpoint of this interim analysis was the cumulative incidence of grade 2 (G2) or higher AEs. The randomized patient allocation